Good management practices of venomous snakes in captivity to produce biological venom-based medicines: achieving replicability and contributing to pharmaceutical industry
Published in Journal of Toxicology and Environmental Health, Part B, 2021
Lucilene Santos, Cristiano Oliveira, Barbara Marques Vasconcelos, Daniela Vilela, Leonardo Melo, Lívia Ambrósio, Amanda da Silva, Leticia Murback, Jacqueline Kurissio, Joeliton Cavalcante, Claudia Vilalva Cassaro, Luciana Barros, Benedito Barraviera, Rui Seabra Ferreira
Animal venoms are a complex mixture of organic and inorganic components (Calvete et al. 2009; Lomonte and Calvete 2017; Theakston and Kamiguti 2002). According to Warrel (2010) “Snake venoms are rich in protein and peptide toxins that have specificity for a wide range of tissue receptors, making them clinically challenging and scientifically fascinating, especially for drug design.” In addition to the unique importance of these toxins in the production of antivenoms, several investigators demonstrated analgesic, antimicrobial, antihypertensive, antiviral, antiparasitic, and antitumor potential (Costa et al. 2014; Da Mata et al. 2017; Mohamed Abd El-Aziz, Garcia Soares, and Stockand 2019).